Pheochromocytoma and paraganglioma (PPGL) · line 1 · Sunitinib monotherapy (metastatic non-MIBG-avid pheochromocytoma/paraganglioma; FIRSTMAPPP)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-SUNITINIB-PHEO |
| ID | IND-PHEO-METASTATIC-1L-SUNITINIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-07-11 |
| Diseases | DIS-PHEOCHROMOCYTOMA |
| Sources | SRC-FIRSTMAPPP-BAUDIN-2024 SRC-NCCN-NET-2025 |
Notes
Coverage-enabling metastatic-disease indication for DIS-PHEOCHROMOCYTOMA, default non-MIBG-avid systemic branch (FIRSTMAPPP evidence). Reuses DRUG-SUNITINIB. expected_outcomes uses OutcomeValue wrappers pointing at SRC-FIRSTMAPPP-BAUDIN-2024; the file under independent review had cited this trial under a 2023 year-suffix id with null DOI/PMID and had deliberately omitted the effect size out of an abundance of caution -- this session independently confirmed the trial via PubMed (PMID 38402886; Lancet 2024;403(10431):1061-1070) and corrected the source id/year and populated the verified 12-month PFS figures (36% vs 19%) rather than leaving them unstated. Requires medical oncology co-lead signoff before clinical publication.
Used By
Algorithms
ALGO-PHEO-1L- ALGO-PHEO-1L
Disease
DIS-PHEOCHROMOCYTOMA- Pheochromocytoma and paraganglioma (PPGL)
Indication
IND-PHEO-METASTATIC-1L-CABOZANTINIB- IND-PHEO-METASTATIC-1L-CABOZANTINIB
Sources
SRC-FIRSTMAPPP-BAUDIN-2024- Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from...